{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-23-013323","form_type":"8-K","ticker":"CVM","cik":"0000725363","company_name":"CEL SCI CORP","filed_at":"2023-10-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.832010+00:00","generated_at":"2026-06-09T15:11:14.195404+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"CEL-SCI's Multikine shows 28% absolute 5-year survival benefit in head & neck cancer target population at ESMO","bullets":["Target population: low PD-L1 (<10%), N0, no extracapsular spread; covers ~145,000 patients/year worldwide.","5-year survival 73% with Multikine vs 45% control (p=0.0015); hazard ratio 0.35, 65% risk reduction.","Pre-surgery disease downstaging observed in 35% of Multikine patients; linked to improved survival.","Pre-application regulatory filings submitted in UK and Europe; plans to file in US and Canada for immediate approval without confirmatory study."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-23-013323","json":"https://secwatch.observer/filing/0001654954-23-013323.json","markdown":"https://secwatch.observer/filing/0001654954-23-013323.md","text":"https://secwatch.observer/filing/0001654954-23-013323.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/725363/000165495423013323/0001654954-23-013323-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/725363/000165495423013323/cvm_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T15:11:14.195404+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}